DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Running, not enrolling

Conditions studied: Pulmonary Disease

In brief

DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign indeterminate pulmonary nodules in high-risk smokers. Ultimately, this study aims to validate molecular as well as clinical and imaging biomarkers of lung cancer in individuals with indeterminate lung nodules.

Key facts

Study ID

NCT04165564

Run by

Boston University

People needed

85

Starts

2020-08-24

Expected to finish

2026-12-01

Last updated by the study team

2026-04-01

Who can join

Age: 46 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Radiologic diagnosis of solid indeterminate pulmonary nodule (0.8 to 2.5 cm) identified in the past 3 months OR semi-solid (mixed density) nodule with solid component of at least 0.6 cm identified in the past 12 months; must be of appropriate size at enrollment.
• CT scan completed within 3 months prior to enrollment
• Able to tolerate all biospecimen collection as required by protocol
• Able to comply with standard of care follow up visits including clinical exams, diagnostic work-ups, and imaging for approximately three years from enrollment
• Able to complete the Patient Lung History questionnaire with study staff
• Arm 1 - Screening
• Age 55-77 years old
• Current and former smokers with 30 pack-years or more(and quit less than 15 years ago)
• Arm 2 - Incidental
• Age > 45 years old
• Current and former smokers with 10 pack-years or more(and quit less than 15 years ago)

You may not qualify if…

• History or previous diagnosis of primary lung cancer, metastatic lung cancer, or any other non-lung cancer within 5 years (not including non-melanoma skin cancer)
• Symptoms of lung cancer (unexplained weight loss 10 lbs or more in 3 months, recent hemoptysis)
• Diagnosis of pure ground glass opacities for the target lesion on chest CT within the last 12 months (i.e., mixed features on the target lesion and pure ground glass opacity on non-target lesions are acceptable as mentioned above)

Where it is running

• University of Alabama, Birmingham — Birmingham, Alabama, United States
• University of California Los Angeles — Los Angeles, California, United States
• VA Greater LA Healthcare System — Los Angeles, California, United States
• Naval Medical Center San Diego — San Diego, California, United States
• University of Iowa — Iowa City, Iowa, United States
• Walter Reed Army Medical Center — Bethesda, Maryland, United States
• VA Boston Healthcare System — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• American College of Radiology [Administrative Site] — Philadelphia, Pennsylvania, United States
• University of Pennsylvania School of Medicine — Philadelphia, Pennsylvania, United States
• Temple University — Philadelphia, Pennsylvania, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Brown University [Administrative Site] — Providence, Rhode Island, United States
• VA Tennessee Valley Healthcare System — Nashville, Tennessee, United States
• MD Anderson Cancer Center [Administrative Site] — Houston, Texas, United States
• Naval Medical Center Portsmouth — Portsmouth, Virginia, United States
• West Virginia University — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.